ArticleCureus2025
PreserFlo MicroShunt Tube Embedded in the Iris: Successful Treatment Using Argon and Neodymium-Doped Yttrium Aluminum Garnet (Nd:YAG) Lasers and Laser Iridotomy for Recurrence Prevention.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The PreserFlo MicroShunt (PMS) (Santen Pharmaceutical, Co., Ltd., Osaka, Japan) procedure is classified as minimally invasive glaucoma surgery (MIGS) and is a type of tube shunt surgery. Tube occlusion in PMS is a rare but significant complication that requires intervention unless caused by temporary thrombi. This report describes a rare case where a PMS tube became completely embedded in the iris, and the condition was successfully managed with the combined use of argon and neodymium-doped yttrium aluminum garnet (Nd:YAG) lasers. A 54-year-old woman with pigmentary glaucoma in her right eye underwent trabeculectomy but failed to achieve adequate intraocular pressure (IOP) control. PMS implantation was performed approximately five months after the initial surgery. Seven months post-implantation, the entire PMS tube became embedded in the iris, leading to IOP elevation. Argon and Nd:YAG lasers were used to relieve the occlusion, followed by laser iridotomy around the tube tip to prevent re-occlusion. The IOP was well-controlled immediately after the laser procedure and remained stable for three months postoperatively, with no recurrence of occlusion or corneal endothelial damage. The combined use of argon and Nd:YAG lasers appears to be a promising and safe treatment option for managing iris-related PMS occlusion and preventing recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.